Literature DB >> 34124669

Porphyromonas gingivalis: where do we stand in our battle against this oral pathogen?

Kaitlind C Howard1, Octavio A Gonzalez2, Sylvie Garneau-Tsodikova1.   

Abstract

Periodontal diseases, such as gingivitis and periodontitis, are inflammatory diseases triggered by pathogenic bacteria that lead to damage of the soft tissue and bone supporting the teeth. Amongst the identified oral periodontopathogenic bacteria, Porphyromonas gingivalis is able to enhance oral dysbiosis, which is an imbalance in the beneficial commensal and periodontal pathogenic bacteria that induces chronic inflammation. Given the critical role of oral pathogenic bacteria like P. gingivalis in the pathogenesis of periodontitis, local and/or systemic antibacterial therapy has been suggested to treat this disease, especially in its severe or refractory forms. Nevertheless, the majority of the antibacterial agents currently used for the treatment of periodontal diseases are broad-spectrum, which harms beneficial bacterial species that are critical in health, inhibit the growth of pathogenic bacteria, contribute in protecting the periodontal tissues to damage and aid in its healing. Thus, the development of more effective and specific antibacterial agents is needed to control oral pathogens in a polymicrobial environment. The strategies for the development of novel antibacterial agents include natural product isolation as well as synthetic and semi-synthetic methodologies. This review presents an overview of the periodontal diseases gingivitis and periodontitis along with current antibacterial treatment options (i.e., classes of antibacterial agents and the mechanism(s) of resistance that hinder their usage) used in periodontal diseases that specifically target oral pathogens such as P. gingivalis. In addition, to help medicinal chemists gain a better understanding of potentially promising scaffolds, this review provides an in-depth coverage of the various families of small molecules that have been investigated as potential anti-P. gingivalis agents, including novel families of compounds, repositioned drugs, as well as natural products. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34124669      PMCID: PMC8152699          DOI: 10.1039/d0md00424c

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  147 in total

1.  EXPERIMENTAL GINGIVITIS IN MAN.

Authors:  H LOE; E THEILADE; S B JENSEN
Journal:  J Periodontol       Date:  1965 May-Jun       Impact factor: 6.993

Review 2.  Bacterial interactions and successions during plaque development.

Authors:  Paul E Kolenbrander; Robert J Palmer; Alexander H Rickard; Nicholas S Jakubovics; Natalia I Chalmers; Patricia I Diaz
Journal:  Periodontol 2000       Date:  2006       Impact factor: 7.589

Review 3.  The clinical effect of scaling and root planing and the concomitant administration of systemic amoxicillin and metronidazole: a systematic review.

Authors:  Dina Zandbergen; Dagmar E Slot; Charles M Cobb; Fridus A Van der Weijden
Journal:  J Periodontol       Date:  2012-05-21       Impact factor: 6.993

4.  Intramolecular cross-coupling of gem-dibromoolefins: a mild approach to 2-bromo benzofused heterocycles.

Authors:  Stephen G Newman; Valentina Aureggi; Christopher S Bryan; Mark Lautens
Journal:  Chem Commun (Camb)       Date:  2009-08-06       Impact factor: 6.222

5.  A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification.

Authors:  Jack G Caton; Gary Armitage; Tord Berglundh; Iain L C Chapple; Søren Jepsen; Kenneth S Kornman; Brian L Mealey; Panos N Papapanou; Mariano Sanz; Maurizio S Tonetti
Journal:  J Clin Periodontol       Date:  2018-06       Impact factor: 8.728

6.  Resveratrol attenuates the pathogenic and inflammatory properties of Porphyromonas gingivalis.

Authors:  Amel Ben Lagha; Elisoa Andrian; Daniel Grenier
Journal:  Mol Oral Microbiol       Date:  2019-06       Impact factor: 3.563

7.  Prevalence of Actinomyces spp. in patients with chronic periodontitis.

Authors:  Paul Vielkind; Holger Jentsch; Klaus Eschrich; Arne C Rodloff; Catalina-Suzana Stingu
Journal:  Int J Med Microbiol       Date:  2015-08-21       Impact factor: 3.473

8.  Antibiotic susceptibility of periodontal Streptococcus constellatus and Streptococcus intermedius clinical isolates.

Authors:  Thomas E Rams; Diane Feik; Joel E Mortensen; John E Degener; Arie J van Winkelhoff
Journal:  J Periodontol       Date:  2014-12       Impact factor: 6.993

9.  Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis.

Authors:  Sheila L Arvikar; Deborah S Collier; Mark C Fisher; Sebastian Unizony; George L Cohen; Gail McHugh; Toshihisa Kawai; Klemen Strle; Allen C Steere
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

10.  Association between polycystic ovary syndrome, oral microbiota and systemic antibody responses.

Authors:  Aliye Akcalı; Nagihan Bostanci; Özgün Özçaka; Banu Öztürk-Ceyhan; Pınar Gümüş; Nurcan Buduneli; Georgios N Belibasakis
Journal:  PLoS One       Date:  2014-09-18       Impact factor: 3.240

View more
  2 in total

Review 1.  Copper-containing nanoparticles: Mechanism of antimicrobial effect and application in dentistry-a narrative review.

Authors:  Xinru Ma; Shiyu Zhou; Xiaoling Xu; Qin Du
Journal:  Front Surg       Date:  2022-08-05

Review 2.  Implications of Porphyromonas gingivalis peptidyl arginine deiminase and gingipain R in human health and diseases.

Authors:  Yoke Chan Chow; Hok Chai Yam; Baskaran Gunasekaran; Weng Yeen Lai; Weng Yue Wo; Tarun Agarwal; Yien Yien Ong; Siew Lee Cheong; Sheri-Ann Tan
Journal:  Front Cell Infect Microbiol       Date:  2022-09-29       Impact factor: 6.073

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.